Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Medicina Interna; Investigators, GenOMICC; Consortium, SCOURGE; Investigators, ISARICC; Team, 23andMe COVID-19; Sepsis Research (the Fiona Elizabeth Agnew Trust); Intensive Care Society; Wellcome Trust; UK Research and Innovation; Department of Health and Social Care (DHSC); BBSRC Institute Program Support Grant; Edinburgh Clinical Academic Track (ECAT) programm; Health Data Research UK; RCUK Innovation Fellowship from the National Productivity Investment Fund; Instituto de Salud Carlos III; Ministerio de Ciencia, Innovación y Universidades (España); Fundacion Amancio Ortega; Fundación Canaria Instituto de Investigación Sanitaria de Canarias; Centro National de Genotipado (CEGEN); Centro de Supercomputacion de Galicia (CESGA); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Apollo - University of Cambridge Repository; GenOMICC Investigators; SCOURGE Consortium; ISARICC Investigators; The 23andMe COVID-19 Team
    • بيانات النشر:
      Springer Science and Business Media LLC, 2023.
    • الموضوع:
      2023
    • نبذة مختصرة :
      Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).
    • File Description:
      application/pdf; text/xml; application/zip; Print-Electronic; 764 - +
    • ISSN:
      1476-4687
      0028-0836
    • الرقم المعرف:
      10.1038/s41586-023-06034-3
    • Rights:
      CC BY
      CC BY NC ND
      URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) .
    • الرقم المعرف:
      edsair.doi.dedup.....e5b6811ee57efdf10443cff80baf8203